Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy

Molecular Therapy

Volumn 19, Issue 10, 2011, Pages 1802-1812

  Kottke, Timothy ^a   Chester, John ^b   Ilett, Elizabeth ^a,b   Thompson, Jill ^a   Diaz, Rosa ^a   Coffey, Matt ^c   Selby, Peter ^b   Nuovo, Gerard ^d   Pulido, Jose ^a   Mukhopadhyay, Debabrata ^e   Pandha, Hardev ^f   Harrington, Kevin ^g   Melcher, Alan ^b   Vile, Richard ^a,b  

^a MAYO CLINIC   (United States)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c ONCOLYTICS BIOTECH INC   (Canada)

^d OHIO STATE UNIVERSITY   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

^f UNIVERSITY OF SURREY   (United Kingdom)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; PACLITAXEL; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REOVIRUS; REOVIRUS INFECTION; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR CELL; VIRUS REPLICATION;

ORTHOREOVIRUS;

EID: 80053566728     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.147     Document Type: Article

References (50)

1. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540. (Pubitemid 351850977)
2. Martuza RL and Zwiebel J (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781-787. (Pubitemid 32691631)
3. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976. (Pubitemid 41766784)
4. Parato, KA, Lichty, BD and Bell, JC (2009). Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther 11: 13-21.
5. Prestwich, RJ, Errington, F, Diaz, RM, Pandha, HS, Harrington, KJ, Melcher, AA et al. (2009). The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 20: 1119-1132.
6. Hu, JC, Coffin, RS, Davis, CJ, Graham, NJ, Groves, N, Guest, PJ et al. (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12: 6737-6747. (Pubitemid 44876843)
7. Senzer, NN, Kaufman, HL, Amatruda, T, Nemunaitis, M, Reid, T, Daniels, G et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27: 5763-5771.
8. Harrington, KJ, Vile, RG, Melcher, A, Chester, J and Pandha, HS (2010). Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 21: 91-98.
9. Yap, TA, Brunetto, A, Pandha, H, Harrington, K and Debono, JS (2008). Reovirus therapy in cancer: has the orphan virus found a home? Expert Opin Investig Drugs 17: 1925-1935.
10. Coffey, MC, Strong, JE, Forsyth, PA and Lee, PW (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334. (Pubitemid 28524498)
11. Hirasawa, K, Nishikawa, SG, Norman, KL, Coffey, MC, Thompson, BG, Yoon, CS et al. (2003). Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348-353. (Pubitemid 36152492)
12. Downward, J (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22. (Pubitemid 37328883)
13. Prestwich, RJ, Errington, F, Ilett, EJ, Morgan, RS, Scott, KJ, Kottke, T et al. (2008). Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 14: 7358-7366.
14. Prestwich, RJ, Errington, F, Steele, LP, Ilett, EJ, Morgan, RS, Harrington, KJ et al. (2009). Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 183: 4312-4321.
15. Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, LP, Kottke, T et al. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381.
16. Forsyth, P, Roldán, G, George, D, Wallace, C, Palmer, CA, Morris, D et al. (2008). A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16: 627-632. (Pubitemid 351315004)
17. Vidal, L, Pandha, HS, Yap, TA, White, CL, Twigger, K, Vile, RG et al. (2008). A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14: 7127-7137.
18. Harrington, KJ, Karapanagiotou, EM, Roulstone, V, Twigger, KR, White, CL, Vidal, L et al. (2010). Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 16: 3067-3077.
19. Comins, C, Spicer, J, Protheroe, A, Roulstone, V, Twigger, K, White, CM et al. (2010). REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16: 5564-5572.
20. Nakashima, H, Kaur, B and Chiocca, EA (2010). Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev 21: 119-126.
21. Willmon, C, Harrington, K, Kottke, T, Prestwich, R, Melcher, A and Vile, R (2009). Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 17: 1667-1676.
22. Qiao, J, Wang, H, Kottke, T, White, C, Twigger, K, Diaz, RM et al. (2008). Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 14: 259-269. (Pubitemid 351378003)
23. Power, AT and Bell, JC (2007). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 15: 660-665. (Pubitemid 46431985)
24. Qiao, J, Kottke, T, Willmon, C, Galivo, F, Wongthida, P, Diaz, RM et al. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44.
25. White, CL, Twigger, KR, Vidal, L, De Bono, JS, Coffey, M, Heinemann, L et al. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 15: 911-920. (Pubitemid 351791478)
26. Ellis, LM and Hicklin, DJ (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
27. Thorpe, PE (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427. (Pubitemid 38173977)
28. Dvorak, HF (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380. (Pubitemid 35266299)
29. Hicklin, DJ and Ellis, LM (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027. (Pubitemid 46202320)
30. Kowanetz, M and Ferrara, N (2006). Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12: 5018-5022. (Pubitemid 44453326)
31. Kottke, T, Hall, G, Pulido, J, Diaz, RM, Thompson, J, Chong, H et al. (2010). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest 120: 1551-1560.
32. Kavallaris, M (2010). Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204.
33. Lolkema, MP, Arkenau, HT, Harrington, K, Roxburgh, P, Morrison, R, Roulstone, V et al. (2011). A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17: 581-588.
34. Zeng, H, Dvorak, HF and Mukhopadhyay, D (2001). Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 276: 26969-26979.
35. Zeng, H, Sanyal, S and Mukhopadhyay, D (2001). Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276: 32714-32719.
36. Cools, J, Mentens, N, Furet, P, Fabbro, D, Clark, JJ, Griffin, JD et al. (2004). Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 64: 6385-6389. (Pubitemid 39297890)
37. Walter-Yohrling, J, Morgenbesser, S, Rouleau, C, Bagley, R, Callahan, M, Weber, W et al. (2004). Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res 10: 2179-2189. (Pubitemid 38375580)
38. Carmeliet, P, Moons, L, Luttun, A, Vincenti, V, Compernolle, V, De Mol, M et al. (2001). Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583. (Pubitemid 32448325)
39. Sei, S, Mussio, JK, Yang, QE, Nagashima, K, Parchment, RE, Coffey, MC et al. (2009). Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 8: 47.
40. Klosowska-Wardega, A, Hasumi, Y, Ahgren, A, Heldin, CH and Hellberg, C (2010). Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor. Melanoma Res.
41. Shaked, Y, Henke, E, Roodhart, JM, Mancuso, P, Langenberg, MH, Colleoni, M et al. (2008). Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263-273.
42. Strieth, S, Eichhorn, ME, Werner, A, Sauer, B, Teifel, M, Michaelis, U et al. (2008). Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res 14: 4603-4611.
43. Nagano, S, Perentes, JY, Jain, RK and Boucher, Y (2008). Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 68: 3795-3802.
44. Griffon-Etienne, G, Boucher, Y, Brekken, C, Suit, HD and Jain, RK (1999). Taxaneinduced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59: 3776-3782. (Pubitemid 29381886)
45. Ottolino-Perry, K, Diallo, JS, Lichty, BD, Bell, JC and McCart, JA (2010). Intelligent design: combination therapy with oncolytic viruses. Mol Ther 18: 251-263.
46. Linardakis, E, Bateman, A, Phan, V, Ahmed, A, Gough, M, Olivier, K et al. (2002). Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 62: 5495-5504.
47. Jevremovic, D, Gulati, R, Hennig, I, Diaz, RM, Cole, C, Kleppe, L et al. (2004). Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. Am J Physiol Heart Circ Physiol 287: H494-H500. (Pubitemid 38955277)
48. Robertson, MJ, Cochran, KJ, Cameron, C, Le, JM, Tantravahi, R and Ritz, J (1996). Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 24: 406-415. (Pubitemid 26098857)
49. Nuovo, GJ (2010). In situ detection of microRNAs in paraffin embedded, formalin fixed tissues and the co-localization of their putative targets. Methods 52: 307-315.
50. Tanaka, S, Iwai, M, Harada, Y, Morikawa, T, Muramatsu, A, Mori, T et al. (2000). Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter. Cancer Gene Ther 7: 1241-1250.